An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial Hypertension
Completed
- Conditions
- Hypertension
- Registration Number
- NCT01201980
- Lead Sponsor
- AstraZeneca
- Brief Summary
This study is aimed to evaluate response rate of the antihypertensive treatment with a calcium antagonist in real life practice, to evaluate patients' quality of life and to collect the following Serbia-specific epidemiology data on hypertension: demographic data, patents characteristics, and patients' management/treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate proportion of patients on antihypertensive pharmacological treatment reaching SBP goals according to the ESC 2007 guidelines (<140 mmHg*). 24 weeks
- Secondary Outcome Measures
Name Time Method To evaluate proportion of patients on antihypertensive pharmacological treatment reaching DBP goals according to the ESC 2007 guidelines (<90 mmHg*). 24 weeks To collect local epidemiological date on patients with hypertension (demographic data; hypertension management data: treatment, treatment changes and tolerability data). 24 weeks To evaluate patients quality of life after 12 and 24 weeks by using patients quality of life questionnaire 24 weeks
Trial Locations
- Locations (1)
Research Site
🇷🇸Sremska Kamenica, Serbia
Research Site🇷🇸Sremska Kamenica, Serbia